This is the latest paper from Dr Agrawal and Professor Borody on AMAT in paediatric Crohn’s disease. “The study provides a valuable and novel proof of concept regarding the applicability of AMAT to a broad range of clinical presentations in paediatric Crohn’s disease patients. We report no significant side effects as a result of a dose escalated, sustained antibiotic regimen andsuggest that AMAT may be more efficacious in the treatment of childhood onset compared with adult onset CD.”
Anti-Mycobacterial Antibiotic Therapy Induces Remission in Active Paediatric Crohn’s Disease
